A 52-year-old man from Delhi presents with recurrent acute gout attacks affecting the first metatarsophalangeal joint. Laboratory investigations show serum uric acid 9.2 mg/dL and 24-hour urinary uric acid excretion 1100 mg/day (normal <800 mg/day). Regarding the biochemical basis of hyperuricemia and urate-lowering therapy, all of the following are true EXCEPT:

Explanation

## Urate-Lowering Therapies and Hyperuricemia Management ### Clinical Context: Overexcretor Gout **Key Point:** This patient has **overexcretor hyperuricemia** (24-hour urinary uric acid >800 mg/day), indicating excessive purine catabolism or dietary purine intake rather than renal underexcretion. The first-line approach is urate-lowering therapy (ULT) combined with acute attack prophylaxis. ### Correct Statements (Options 0, 1, 2) #### Option 0: Febuxostat **High-Yield:** Febuxostat is a **non-purine selective inhibitor** of xanthine oxidase (unlike allopurinol, which is a purine analogue). It is more potent and selective, with a longer half-life. Importantly, it does **not require dose adjustment in renal impairment** (CKD stage 1–3), making it advantageous in patients with reduced renal function. #### Option 1: Probenecid **Clinical Pearl:** Probenecid is a **uricosuric agent** that inhibits URAT1 (urate transporter 1) in the proximal tubule, blocking urate reabsorption and increasing urinary uric acid excretion. It is effective in underexcretors but **contraindicated in overexcretors** (like this patient) because it would worsen hyperuricemia if renal excretory capacity is already maximal. #### Option 2: Rasburicase **Key Point:** Rasburicase is a **recombinant uricase** (derived from *Aspergillus flavus*) that catalyzes uric acid → allantoin conversion. It is **indicated for acute tumor lysis syndrome (TLS)** in hematologic malignancies, where rapid uric acid reduction is critical. It is NOT used for chronic gout management. ### The Incorrect Statement (Option 3) — THE ANSWER **Warning:** Pegloticase is a **PEGylated recombinant mammalian uricase** that degrades uric acid to allantoin. However, it is **NOT suitable for long-term monotherapy** in chronic gout because: 1. **Immunogenicity:** Pegloticase is highly immunogenic; approximately 40–50% of patients develop anti-pegloticase antibodies, leading to loss of efficacy and infusion reactions (including anaphylaxis). 2. **Indication:** Pegloticase is reserved for **refractory gout** (inadequate response to allopurinol/febuxostat) or **severe tophaceous gout**, not routine chronic gout. 3. **Maintenance:** Patients on pegloticase require: - Co-administration of immunosuppressants (e.g., methotrexate, mycophenolate) to reduce antibody formation - Regular infusions (every 2 weeks) with careful monitoring - It is not a simple monotherapy option **Mnemonic:** **PEGLOTICASE = Problematic, Expensive, Generates antibodies, Limited to refractory cases, Only with immunosuppression** ### Comparison Table: Xanthine Oxidase Inhibitors and Uricase | Agent | Class | Mechanism | Renal Adjustment | Immunogenicity | Use | | --- | --- | --- | --- | --- | --- | | Allopurinol | XOI (purine analogue) | Competitive XO inhibition | Yes (CKD) | Low | First-line ULT | | Febuxostat | XOI (non-purine) | Selective XO inhibition | No (CKD 1–3) | Low | Alternative ULT | | Rasburicase | Uricase | Uric acid → Allantoin | Yes | Moderate | Acute TLS only | | Pegloticase | PEGylated uricase | Uric acid → Allantoin | No | **High (40–50%)** | Refractory gout + IS | [cite:Harrison's Principles of Internal Medicine 21e Ch 348; Robbins & Cotran Pathologic Basis of Disease 10e Ch 24]